Reply to the letter to the editor “Stenosis severity indices cannot reflect lumen loss in stent trials”

EuroIntervention 2018;14:839-840. DOI: 10.4244/EIJ-D-17-01073R

Taku Asano
Taku Asano1,2, MD; Yoshinobu Onuma3,4, MD, PhD; Johan H.C. Reiber5, PhD; Patrick W. Serruys6*, MD, PhD
1. Academic Medical Center, Amsterdam-Zuidoost, the Netherlands; 2. St. Luke’s International Hospital, Tokyo, Japan; 3. Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands; 4. Cardialysis BV, Rotterdam, the Netherlands; 5. Department of Radiology, Leiden

We appreciate the interest shown by Lauri et al in the PIONEER QFR substudy1. We analysed quantitative flow ratio (QFR) at three different time points (pre-procedure, post-procedure and at nine months after the index procedure) and compared the functional significance between the BuMA™ sirolimus-eluting stent (SINOMED, Tianjin, China) and Resolute™ zotarolimus-eluting stent (Medtronic, Minneapolis, MN, USA). There was no need for concern regarding preprocedural QFR because, at pre-procedure, mean diameter stenosis (DS) was 60.1±10.3% for BuMA and 60.7±10.8% for Resolute. Post-procedure and at nine months after the index procedure, mean DS ranged between 9% and 17%. As Lauri et al pointed out, QFR ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients

Latest news